GZMB and neoplasm: Since granzyme B activity is important for tumor immunity,[29] we contend that alterations in granzyme B activity can serve as a meaningful blood biomarker to evaluate changes in the immune status of tumor tissues, thereby contributing to early tumor detection and better classification of patients that respond to immune checkpoint inhibitors.